302 related articles for article (PubMed ID: 21889769)
1. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Brautbar A; Covarrubias D; Belmont J; Lara-Garduno F; Virani SS; Jones PH; Leal SM; Ballantyne CM
Atherosclerosis; 2011 Dec; 219(2):737-42. PubMed ID: 21889769
[TBL] [Abstract][Full Text] [Related]
2. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
[TBL] [Abstract][Full Text] [Related]
3. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Brautbar A; Virani SS; Belmont J; Nambi V; Jones PH; Ballantyne CM
J Lipid Res; 2012 Mar; 53(3):556-560. PubMed ID: 22236405
[TBL] [Abstract][Full Text] [Related]
4. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
Brautbar A; Barbalic M; Chen F; Belmont J; Virani SS; Scherer S; Hegele RA; Ballantyne CM
J Lipid Res; 2013 Jul; 54(7):1980-7. PubMed ID: 23633496
[TBL] [Abstract][Full Text] [Related]
5. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
6. Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia.
Sharma A; Joshi PH; Rinehart S; Thakker KM; Lele A; Voros S
J Cardiovasc Transl Res; 2014 Jun; 7(4):465-74. PubMed ID: 24723075
[TBL] [Abstract][Full Text] [Related]
7. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Ma L; Ballantyne CM; Belmont JW; Keinan A; Brautbar A
J Lipid Res; 2012 Nov; 53(11):2425-8. PubMed ID: 22896670
[TBL] [Abstract][Full Text] [Related]
8. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
[TBL] [Abstract][Full Text] [Related]
12. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
14. Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region.
OʼBrien SE; Schrodi SJ; Ye Z; Brilliant MH; Virani SS; Brautbar A
J Cardiovasc Pharmacol; 2015 Aug; 66(2):183-8. PubMed ID: 25900265
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
[TBL] [Abstract][Full Text] [Related]
16. Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults.
Komurcu-Bayrak E; Onat A; Poda M; Humphries SE; Palmen J; Guclu F; Can G; Erginel-Unaltuna N
Clin Chem Lab Med; 2008; 46(6):778-84. PubMed ID: 18601598
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Jones PH; Bays HE; Davidson MH; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Clin Drug Investig; 2008; 28(10):625-34. PubMed ID: 18783301
[TBL] [Abstract][Full Text] [Related]
18. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
Pepine CJ; Jacobson TA; Carlson DM; Kelly MT; Setze CM; Gold A; Stolzenbach JC; Williams LA
Clin Cardiol; 2010 Oct; 33(10):609-619. PubMed ID: 20960535
[TBL] [Abstract][Full Text] [Related]
19. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
